Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel, +27

New England Journal of Medicine

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel, +30

New England Journal of Medicine

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

Takaaki Tokito, Koichi Azuma, Akihiko Kawahara, +8

European Journal of Cancer

Concurrent ChemoradiotherapyCancer ImmunosurveillancePd-l1 ExpressionCd8+ Til DensityMedicine +8

Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer

Madoka Kimura, Tateaki Naito, Hirotsugu Kenmotsu, +14

Supportive Care in Cancer

Prognostic ImpactCancer CachexiaMedicineCancer ManagementPathology +7

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer

Hidenobu Ishii, Koichi Azuma, Akihiko Kawahara, +6

Journal of Thoracic Oncology

MedicineImmunologyCell DeathBronchial NeoplasmLung Cancer +5

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu, +13

Journal of Thoracic Oncology

Translational MedicineAntibioticsPretreated NsclcPathologyPharmacotherapy +3

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients

Norikazu Matsuo, Koichi Azuma, Kazuko Sakai, +8

Scientific Reports

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples

Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, +6

Oncotarget

EngineeringImmunologyDna AnalysisPathologyTumor Biology +18

Phase II study of tepotinib in NSCLC patients with <i>MET</i>ex14 mutations.

Paul K. Paik, Rémi Veillon, Alexis B. Cortot, +17

Journal of Clinical Oncology

PathologyPhase Ii StudyOncologyMetronomic TherapyMolecular Diagnostics +15

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study

Hidehito Horinouchi, Naoyuki Nogami, Hideo Saka, +10

Cancer Science